196 related articles for article (PubMed ID: 30511296)
21. DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort.
Lindqvist U; Wernroth ML; Husmark T; Larsson P; Geijer M; Teleman A; Theander E; Alenius GM
Clin Exp Rheumatol; 2017; 35(6):936-942. PubMed ID: 28628468
[TBL] [Abstract][Full Text] [Related]
22. Psoriatic arthritis: is it time to treat-to-target or target to treat?
Lubrano E; Perrotta FM
Clin Rheumatol; 2017 Dec; 36(12):2633-2635. PubMed ID: 29067586
[TBL] [Abstract][Full Text] [Related]
23. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature.
Gossec L; McGonagle D; Korotaeva T; Lubrano E; de Miguel E; Østergaard M; Behrens F
J Rheumatol; 2018 Jan; 45(1):6-13. PubMed ID: 29142032
[TBL] [Abstract][Full Text] [Related]
24. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis.
Eder L; Thavaneswaran A; Chandran V; Cook RJ; Gladman DD
Ann Rheum Dis; 2015 May; 74(5):813-7. PubMed ID: 24431392
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
Lubrano E; Scriffignano S; Azuaga AB; Ramirez J; Cañete JD; Perrotta FM
RMD Open; 2020 Mar; 6(1):. PubMed ID: 32179713
[TBL] [Abstract][Full Text] [Related]
26. Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity.
Perruccio AV; Got M; Li S; Ye Y; Gladman DD; Chandran V
J Rheumatol; 2020 Mar; 47(3):362-368. PubMed ID: 31203221
[TBL] [Abstract][Full Text] [Related]
27. Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
Wabe NT; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee AT; Spargo LD; Metcalf RG; Hall C; Proudman SM; Wiese MD
J Rheumatol; 2016 Sep; 43(9):1643-9. PubMed ID: 27422892
[TBL] [Abstract][Full Text] [Related]
28. Measurement properties of the minimal disease activity criteria for psoriatic arthritis.
Coates LC; Strand V; Wilson H; Revicki D; Stolshek B; Samad A; Chung JB; Gladman D; Mease PJ
RMD Open; 2019; 5(2):e001002. PubMed ID: 31565243
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis.
Zardin-Moraes M; da Silva ALFA; Saldanha C; Kohem CL; Coates LC; Henrique LR; Palominos PE; Chakr RMDS
J Rheumatol; 2020 Jun; 47(6):839-846. PubMed ID: 31575702
[TBL] [Abstract][Full Text] [Related]
30. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis.
Iannone F; Nivuori M; Fornaro M; Venerito V; Cacciapaglia F; Lopalco G
Rheumatology (Oxford); 2020 Jul; 59(7):1599-1606. PubMed ID: 31652315
[TBL] [Abstract][Full Text] [Related]
31. What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?
Bakirci S; Solmaz D; Al Osaimi N; Dalkilic E; Can M; Erden A; Ozisler C; Cinar M; Kilic L; Küçük A; Omma A; Yildiz F; Doğru A; Tufan A; Esmen SE; Akar S; Kalyoncu U; Aydin SZ;
Clin Exp Rheumatol; 2019; 37(5):808-812. PubMed ID: 30767863
[TBL] [Abstract][Full Text] [Related]
32. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
Mease PJ; Heckaman M; Kary S; Kupper H
J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
[TBL] [Abstract][Full Text] [Related]
33. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.
Coates LC; Helliwell PS
Arthritis Care Res (Hoboken); 2010 Jul; 62(7):965-9. PubMed ID: 20589696
[TBL] [Abstract][Full Text] [Related]
34. Treat-to-target in PsA: methods and necessity.
Dures E; Shepperd S; Mukherjee S; Robson J; Vlaev I; Walsh N; Coates LC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32071281
[TBL] [Abstract][Full Text] [Related]
35. Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America.
Soriano ER; Zazzetti F; Alves Pereira I; Maldonado Cocco J; Feijó Azevedo V; Guerra G; Bautista-Molano W; Casasola JC; Vega Morales D; Gil DR; Lobosco S; Lawson F
Clin Rheumatol; 2020 Jun; 39(6):1859-1869. PubMed ID: 31993888
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
[TBL] [Abstract][Full Text] [Related]
37. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
Queiro R; Cañete JD
Clin Rheumatol; 2018 Mar; 37(3):661-666. PubMed ID: 29380165
[TBL] [Abstract][Full Text] [Related]
38. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
[TBL] [Abstract][Full Text] [Related]
39. Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?
Tucker LJ; Ye W; Coates LC
Curr Rheumatol Rep; 2018 Sep; 20(11):71. PubMed ID: 30229387
[TBL] [Abstract][Full Text] [Related]
40. Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study.
Gratacós J; Pablos JL; de Miguel E; Juanola X; Fernández-Carballido C; Ariza R; Terradas-Montana P; Sastré C; Sanabra C;
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):204-210. PubMed ID: 37061282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
